Should I Buy ACHV? ACHV 2026 Analysis

Should You Buy Achieve Life Sciences Inc (ACHV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.820

1 Day change

-2.76%

52 Week Range

6.030

Analysis Updated At

2026/03/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Achieve Life Sciences Inc (ACHV) does not present a strong buy opportunity at this time for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive signals from technical indicators, proprietary trading signals, and financial performance, and there are no recent significant catalysts or influential trades to support immediate action.

Technical Analysis

The MACD is negatively expanding, RSI is neutral at 38.056, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 4.209, with support at 4.032 and resistance at 4.385, suggesting limited upside potential in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment, but the overall options activity is minimal, with low volume and open interest, reducing its significance.

Technical Summary

Sell

Buy

Positive Catalysts

Analyst sentiment is positive, with a Buy rating and a $12 price target. The analyst views the absence of Chantix competition as a favorable development for ACHV's cytisinicline approval prospects.

Neutral/Negative Catalysts

No recent news or significant trading trends from hedge funds, insiders, or Congress. Financial performance remains weak, with negative net income and declining EPS.

Financial Performance

In Q3 2025, revenue remained stagnant at $0, net income improved slightly to -$14.44M (up 15.42% YoY), but EPS dropped to -0.28 (down 22.22% YoY). The company shows no signs of revenue generation or profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating with a $12 price target, citing the absence of Chantix competition as a positive for cytisinicline's approval prospects. However, no other analyst updates or changes in price targets were noted.

2 Analyst Rating

Wall Street analysts forecast ACHV stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.900

Low

Averages

15.5

High

Current: 2.900

Low

Averages

15.5

High

H.C. Wainwright

maintain

$12

AI Analysis

2026-02-06

Reason

H.C. Wainwright

Price Target

$12

AI Analysis

2026-02-06

maintain

Reason

H.C. Wainwright views Pfizer's (PFE) launch of Chantix among the 30 medicines it placed on the White House's direct-to-consumer site, TrumpRx, as "a significant positive" for Achieve Life Sciences (ACHV) and cytisinicline, arguing that the news removes the potential of Pfizer bringing Chantix back to market and putting any marketing dollars behind the product. The move to include Chantix on TrumpRx is "not random or economically driven," but rather likely a concession to the Make America Healthy Movement within the current administration, which bodes well for the potential for cytisinicline's chances of approval by the current PDUFA date on June 20, adds the analyst, who has a Buy rating and $12 price target on Achieve shares.

JMP

Jason Butler

Outperform

initiated

$19

2025-11-25

Reason

JMP

Jason Butler

Price Target

$19

2025-11-25

initiated

Outperform

Reason

Citizens JMP analyst Jason Butler initiated coverage of Achieve Life Sciences with an Outperform rating and $19 price target. Achieve is developing cytisinicline, a nicotine dependence treatment for smoking cessation in adults, the analyst tells investors in a research note. The firm believes cytisinicline has a "highly differentiated" profile to Chantix and can both supplant and grow the current market.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACHV

Unlock Now

ACHV Should I Buy

ACHV Should I Buy

Should You Buy Achieve Life Sciences Inc (ACHV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch